FDA Policy for REMS Reqmts during COVID-19
Health Care, Pharma Industry, Strategic Planning
FDA is issuing this guidance to communicate its temporary policy for certain risk evaluation and mitigation strategies (REMS) requirements for the duration of the coronavirus pandemic public health emergency.
Read the Policy now
Related Education Resources.
All Resources2023 EKF Workshop - Getting Clinical Trial Supplies a Seat at the Table
Topics: EKF - 2023, Project Management
Presentation
Members
2023 EKF Workshop - Expanded Access
Topics: EAP, EKF - 2023
Presentation
Members
Envisioning the Future of Clinical Supply Chains in the Next 10 Years
Topic: Supply Chain
Executive Summary
Members
